News · 26 weeks490%
2025-12-142026-06-07
Mix2790d
- Insider15(56%)
- SEC Filings7(26%)
- Other3(11%)
- Earnings2(7%)
Latest news
25 items- INSIDERChief Executive Officer Treace John T. bought $177,915 worth of shares (50,000 units at $3.56), increasing direct ownership by 0.69% to 7,323,833 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERChief Executive Officer Treace John T. bought $340,589 worth of shares (115,520 units at $2.95), increasing direct ownership by 2% to 7,273,833 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- SECTreace Medical Concepts Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- INSIDERDirector Jain Deepti was granted 30,000 shares, increasing direct ownership by 43% to 100,243 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERDirector Bakewell John K was granted 30,000 shares, increasing direct ownership by 17% to 204,056 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERDirector Kiernan Jane E was granted 30,000 shares, increasing direct ownership by 47% to 93,949 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERDirector Berry Lance A was granted 30,000 shares, increasing direct ownership by 67% to 74,593 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERDirector Hanna Betsy was granted 30,000 shares, increasing direct ownership by 66% to 75,243 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERDirector Hamilton Lawrence W was granted 30,000 shares, increasing direct ownership by 68% to 74,056 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.SCHEDULE 13G/A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
- INSIDERChief Executive Officer Treace John T. bought $375,505 worth of shares (153,763 units at $2.44), increasing direct ownership by 2% to 7,158,313 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Treace Medical Concepts Inc.SCHEDULE 13G - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Subject)
- SECSEC Form S-8 filed by Treace Medical Concepts Inc.S-8 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- SECSEC Form 10-Q filed by Treace Medical Concepts Inc.10-Q - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- SECTreace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- PRTreace Medical Concepts Reports First Quarter 2026 Financial ResultsPONTE VEDRA, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today reported financial results for the first quarter ended March 31, 2026. Recent Highlights Generated revenue of $47.2 million in first quarter 2026 compared to $52.6 million in the same period in 2025. Reported first quarter 2026 net loss of $(18.0) million and adjusted EBITDA of $(5.5) million in the first quarter 2026.Cash, cash equivalents, and marketable securities totaled $51.9 million as of March 31, 2026, representing an increase
- PRTreace to Report First Quarter 2026 Financial Results on May 8, 2026PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and ar
- INSIDERSEC Form 4 filed by Hair Mark4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- SECTreace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Leadership Update8-K - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- PRTreace Announces First Surgical Cases with the SuperBite™ Compression Screw SystemPONTE VEDRA, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first cases utilizing its SuperBite™ Compression Screw System. SuperBite™ screws are engineered to deliver advanced compression through a variable thread pitch and optimized headless design, with its self-drilling and countersinking features enabling rapid screw insertion. The screw implants also incorporate a beveled head design with smoothed edges, making them ideal for both minimally inva
- SECSEC Form DEF 14A filed by Treace Medical Concepts Inc.DEF 14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- SECSEC Form DEFA14A filed by Treace Medical Concepts Inc.DEFA14A - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Filer)
- INSIDERSEC Form 4 filed by Hair Mark4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERChief Executive Officer Treace John T. covered exercise/tax liability with 7,083 shares, decreasing direct ownership by 0.10% to 7,004,550 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
- INSIDERChief Financial Officer Hair Mark covered exercise/tax liability with 4,659 shares, decreasing direct ownership by 0.54% to 863,549 units (SEC Form 4)4 - TREACE MEDICAL CONCEPTS, INC. (0001630627) (Issuer)
TMCI FAQ
7 questionsWhat does Treace Medical Concepts Inc. do?
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser...Where does TMCI stock trade?
Treace Medical Concepts Inc. (TMCI) is listed on NASDAQ.What sector and industry is TMCI in?
Treace Medical Concepts Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Treace Medical Concepts Inc. go public?
Treace Medical Concepts Inc. (TMCI) completed its IPO in 2021.What are analysts saying about TMCI?
Treace Medical Concepts Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Underweight with a $500.00 price target on 2025-11-07. Recent price targets range from $500.00 to $1600.00.What companies are similar to TMCI?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare TMCI side-by-side with any of them on Quantisnow.How can I track TMCI on Quantisnow?
Quantisnow aggregates Treace Medical Concepts Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TMCI to receive live email and push alerts on every new disclosure.